Equillium, Inc.
Close on Oct 19, 2026
- Market cap
- $138.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-0.04 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | $-0.06 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | $0 | $-0.04 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $0 | $-0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | $4.40M | $-0.16 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $12.20M | $0.00 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 23, 2024 | After market close | – | – | – |
Press releases
Announcements Equillium filed with the SEC
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Risks Related to Our Financial Position and Need for Additional Capital
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Equillium Announces Feedback from the U.S. Food and Drug Administration
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
EQ101: Phase 2 Topline Data in
Other events · EX-99.1 to Form 8-K
Equillium Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Results of operations · EX-99.1 to Form 8-K
E QUILLIUM , I NC .
Executive or director change · Other events · EX-99.1 to Form 8-K
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
Results of operations · Other events · EX-99.1 to Form 8-K
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Results of operations · Other events · EX-99.2 to Form 8-K
inherent in the Company’s “potential,” “continue” and “ongoing,” or the negative of these terms, or other business, including without limitation, the risks described in the Company’s filings comparable
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Results of operations · EX-99.1 to Form 8-K
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
Agreement terminated · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the
Material agreement · Other events · EX-99.1 to Form 8-K
Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab 6 December 2022 Exhibit 99.2
Material agreement · Other events · EX-99.2 to Form 8-K
Equillium Reports Third Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
EQUALISE Interim Data Type B: Lupus
Other events · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.2 to Form 8-K
On September 6, 2022, Equillium, Inc., or Equillium, Equillium Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary
Other events · EX-99.3 to Form 8-K
Equillium to Acquire Metacrine in All-Stock Transaction
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. September 7, 2022 Exhibit 99.2
Material agreement · Other events · EX-99.2 to Form 8-K
Equillium Reports Second Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Equillium Reports First Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab
Regulation FD disclosure · EX-99.1 to Form 8-K
Equillium Announces Appointment of Barbara Troupin to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Therapeutics 16 February 2022 Exhibit 99.2
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Equillium Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K